Sodium metavanadate affected control and streptozotocin-diabetic rat liver golgi complexes

Wojciech Dabroś1, Anna Goc, Bohdan Turyna

  • 1Department of Pathomorphology, Jagiellonian University Collegium Medicum, Kraków. mpdabros@cyf-kr.edu.pl

Insights

Metavanadate treatment in diabetic rats did not normalize Golgi enzyme activity or blood sugar levels. However, it did reduce severe ultrastructural damage in liver Golgi complexes, suggesting a protective role against diabetes-induced cellular changes.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Endocrinology

Background:

  • Streptozotocin (STZ)-induced diabetes causes significant biochemical and morphological alterations in rat liver Golgi complexes.
  • Golgi complexes serve as a valuable model for assessing drugs with cytoprotective or normalizing effects in diabetes.

Purpose of the Study:

  • To investigate the effects of metavanadate on STZ-induced diabetic rat liver Golgi complexes.
  • To evaluate metavanadate's impact on Golgi marker enzyme activity and ultrastructure in diabetic models.

Main Methods:

  • Four groups of rats were used: control (C), STZ-diabetic (D), control treated with metavanadate (C+V), and diabetic treated with metavanadate (D+V).
  • Metavanadate (1.5 mM) was administered in drinking solution for 7 days.
  • Evaluations included body weight, fluid/food intake, blood glucose, Golgi galactosyltransferase (GalT) activity, and electron microscopy for ultrastructural analysis.

Main Results:

  • Metavanadate treatment reduced body weight loss and fluid/food intake in diabetic rats, but did not achieve euglycemia.
  • Galactosyltransferase (GalT) activity was significantly reduced in metavanadate-treated and diabetic groups compared to controls.
  • Electron microscopy revealed giant intracytoplasmic vacuoles and ultrastructural changes in metavanadate-treated groups; however, diabetic rats treated with metavanadate showed fewer advanced changes and more ring-like Golgi structures.

Conclusions:

  • Metavanadate treatment did not normalize Golgi membrane preparations or marker enzyme activity in diabetic rats.
  • Despite not normalizing key biochemical markers, metavanadate offered protection against severe ultrastructural damage in liver Golgi complexes of diabetic rats.
  • Further research is needed to understand the protective mechanisms of vanadium compounds in diabetes-related cellular pathology.

Related Concept Videos